regulatory status raises a handful of sensible questions. This page answers them in order, starting with the fundamentals and moving to applications.
This page was last updated on 2025-09-12 and is reviewed periodically as new material appears.
AOD-9604 has been investigated mainly in the context of body fat and metabolic endpoints. Some early animal and small human studies reported changes in fat mass or lipid markers, but findings were not uniform. Larger, well-controlled trials that would establish efficacy are lacking in the public literature. As a result, claims about weight loss or metabolic benefit remain investigational rather than established. The distinction between a research finding and a proven clinical outcome is central to discussing this peptide.
Regulatory bodies have taken different approaches to AOD-9604. It is not approved as a prescription medicine by major agencies such as the U.S. Food and Drug Administration or the European Medicines Agency. In sport, the World Anti-Doping Agency prohibits peptide hormones, growth factors, and related substances, and AOD-9604 has been treated as a prohibited substance. These regulatory decisions reflect concerns about safety, efficacy, and potential misuse rather than proof of benefit.
Detection of AOD-9604 in biological samples relies on analytical techniques capable of distinguishing a small synthetic peptide from related endogenous sequences. Liquid chromatography coupled with tandem mass spectrometry is commonly used for confirmatory analysis. Sample preparation may involve immunoaffinity enrichment or solid-phase extraction to concentrate the peptide. Because the molecule is small and may be present at low concentrations, assay sensitivity and specificity are ongoing analytical challenges. Laboratories also validate methods against reference materials when available.
Regulatory interest in AOD-9604 increased after high-profile anti-doping cases involving peptide products. In some cases, the substance was supplied under alternative names or in compounded preparations, complicating traceability. Sports tribunals and anti-doping panels have discussed whether the peptide was explicitly banned at the time of use, leading to clarifications by the World Anti-Doping Agency. For consumers and researchers, the legal status can vary by jurisdiction, and products marketed as research chemicals may lack independent quality verification.
| Property | Value | Notes |
|---|---|---|
| Regulatory status | Not approved as a medicine | Major agencies have not authorized it for therapeutic use. |
| Anti-doping status | Prohibited in sport | Listed among peptide hormones and related substances. |
| Primary research area | Metabolic and body-composition effects | Studies often examine fat mass or lipid markers. |
| Human evidence | Limited and mixed | Public data do not establish clinical efficacy. |
| Analytical detection | LC-MS and immunoassays | Methods vary in sensitivity and validation. |
AOD-9604 is a synthetic peptide that corresponds to a short section of human growth hormone. It is commonly identified as hGH fragment 176-191 because its sequence matches residues at the C-terminal end of the hormone. The molecule contains sixteen amino acids and is made by solid-phase peptide synthesis. Researchers study it for metabolic effects rather than for the growth-promoting actions associated with full human growth hormone. Its small size distinguishes it from the complete 191-amino-acid hormone.
Several names appear in scientific and commercial settings. AOD9604 and AOD-9604 are development codes used interchangeably, while hGH fragment 176-191 describes the same region. The peptide includes a disulfide bond between two cysteine residues, which helps shape its three-dimensional structure. Different suppliers may provide acetate or other salt forms, and purity can vary. These differences matter because analytical tests and biological assays can respond to the specific form being studied.
Early interest in AOD-9604 centered on whether a fragment of human growth hormone could influence fat metabolism without the broader effects of the full hormone. Cell and animal studies reported changes in fat storage and breakdown. Human trials followed, but the results were not strong enough to secure regulatory approval. The compound remains available for laboratory research, and its clinical potential is still described as uncertain. Studies continue to examine its activity and safety profile.
Proposed mechanisms for AOD-9604 focus on fat cells. Laboratory studies suggest the peptide can increase lipolysis, the breakdown of stored fat, and reduce lipogenesis, the formation of new fat. Unlike full human growth hormone, it does not appear to stimulate substantial IGF-1 production in the studies reported so far. Some evidence points to beta-adrenergic signaling, but the precise receptor targets and downstream pathways remain unresolved. The fragment is not thought to act through the classical growth hormone receptor.
Clinical development of AOD-9604 included trials in people with obesity. Reports from early-phase and mid-phase studies described modest or inconsistent changes in body weight. A phase IIb program did not meet its primary endpoint, and the compound was not approved for medical use. Differences in formulation, delivery route, and participant characteristics may explain some of the variation. Later investigations explored whether the peptide might have effects in other tissues, including cartilage.
Regulatory treatment of AOD-9604 is shaped by its classification as a peptide hormone. The World Anti-Doping Agency lists it as a prohibited substance, and many national anti-doping organizations adopt that list. It does not hold approval as a prescription medicine in the United States, the European Union, or other major markets. Products sold online are frequently labeled for research use only and may not undergo independent quality testing. Import and possession rules differ by country, so legal status depends on local law.
== Toxicity == The Pompilidae family of spider wasps is known for its powerful and painful sting that is used to paralyse arachnids. Social wasps readily attack any threat to their queen and colony and are the only type of insects responsible for medically significant incidents with humans. However, PMTXs are produced by solitary spider wasps and since solitary wasps do not have a colony to defend, humans normally will not be stung by these wasps. PMTX is not listed by IARC, which suggests that there is no indication of carcinogenicity for humans, other information about the effects of PMTX on humans is currently not available. However, it is thought that it won't have a big impact on humans due to the difference in neurological setup between humans and arachnids. What is known is that being stung by a spider wasp causes local pain and swelling, and some people might have an allergic reaction to the sting which can be dangerous. The symptoms of a spider wasp sting, apart from the allergic reaction, can be treated with a cold compress. Even though humans usually will not be stung by these wasps, there have been scientists that deliberately extensively provoked spider wasps similar to PMTX-producing spider wasps, to have them stung by these animals for research on the pain inflicted by these insects. Because of these individuals, it is known that though spider wasp venom causes paralysis in their arthropod prey, they inflict intense pain that remains for around five minutes onto vertebrates such as humans.
Clomipramine is the only TCA that has been shown to be effective in the treatment of OCD and that is approved by the FDA for the treatment of OCD; the other TCAs failed clinical trials for this indication, likely due to insufficient serotonergic activity.
Tigecycline is active against many Gram-positive bacteria, Gram-negative bacteria and anaerobes – including activity against methicillin-resistant Staphylococcus aureus (MRSA), Stenotrophomonas maltophilia, Haemophilus influenzae, and Neisseria gonorrhoeae (with MIC values reported at 2 μg/mL) and multi-drug resistant strains of Acinetobacter baumannii. It has no activity against Pseudomonas spp. or Proteus spp. The drug is licensed for the treatment of skin and soft tissue infections as well as intra-abdominal infections. Tigecycline is also active against Clostridioides difficile strains. Most C. difficile isolates have MICs <0.25 for tigecycline, The European Society of Clinical Microbiology and Infection recommends tigecycline as a potential salvage therapy for severe and/or complicated or refractory Clostridoides difficile infection. Tigecycline can also be used in vulnerable populations such as immunocompromised patients or patients with cancer.
The game's plot twist, where the player discovers that the player-character Jack has been coerced into events by the trigger phrase, "Would you kindly...", is considered one of the strongest narrative elements of video games to that point. In homage to BioShock, Black Mirror's video game-centric episode "Playtest" includes the phrase. A sequel, BioShock 2, was announced in 2008, with its development led by 2K Marin. BioShock 2 was released for Windows PC, Mac, Xbox 360, and the PlayStation 3 worldwide on February 9, 2010. Irrational Games developed BioShock Infinite, taking place aboard the collapsing air-city of Columbia in the year 1912. Infinite involves the possibilities of multiple universes. In one scene, the game take place at the lighthouse and bathysphere terminus of Rapture as part of this exploration. However, no direct canonical connection is given in the main game. The episodic expansion, Burial at Sea, takes place in Rapture in 1959, before the war between Atlas and Ryan, while continuing the story of Booker and Elizabeth. This content links the two stories while providing expansion on the causes and behind-the-scenes events alluded to by the in-game background from BioShock. After completing BioShock Infinite and its expansion, Levine announced that he was restructuring Irrational Games to focus on smaller, narrative-driven titles. 2K Games continues to hold on to the BioShock intellectual property and plans to continue to develop games in this series.
Sources: en.wikipedia.org
== Appetite and circadian rhythms == Dynorphins are important in maintaining homeostasis through appetite control and circadian rhythms. Przewlocki et al. found that, during the day, dynorphins are naturally elevated in the neurointermediate lobe of the pituitary (NI pituitary) and depressed in the hypothalamus. This pattern is reversed at night. In addition, mice deprived of food and water, or of water alone, had increased levels of dynorphin in the hypothalamus during the day. Deprivation of water alone also decreased the dynorphin levels in the NI pituitary. These findings led Przewlocki et al. to conclude that dynorphins are essential in maintaining homeostasis. Dynorphin has been implicated as an appetite stimulant. A number of studies in rats have shown that increasing the dynorphin levels stimulates eating. Opioid antagonists, such as naloxone, can reverse the effects of elevated dynorphin. This inhibition is especially strong in obese animals or animals that have access to particularly appealing food. Inui et al. found that administering dynorphin to dogs increased both their food and water intake. Dynorphin plays a role in the eating behavior of hibernating animals. Nizeilski et al. examined dynorphin levels in the ground squirrel, which undergoes periods of excessive eating and periods of starvation before winter. They found that dynorphin levels increased during the starvation periods. Berman et al. studied the levels of dynorphin during periods of food restriction.
== Acquisitions and expansion == In 2012, the company acquired Stanford Refrigerated Warehouses and Castle & Cooke Cold Storage; Bill Hendricksen of Castle & Cooke then joined Lineage as CEO. Hendricksen was succeeded by W. Gregory Lehmkuhl, in July 2015. Lineage subsequently moved its headquarters from Irvine, California to Novi, Michigan. In April 2013, the company received a $220 million loan, and acquired Seattle Cold Storage and a University Park, Illinois facility. By 2014, most Lineage customers were food producers requiring cold chain warehousing, transportation, and logistics; to meet demand, the company concentrated on automation and acquisition. In March 2014, the company agreed to purchase Millard Refrigerated Services for about $1 billion, its largest acquisition to date, making Lineage "the second-largest temperature-controlled warehousing and logistics company in the world." In the same year, Lineage acquired Loop Cold Storage, Oneida Cold Storage & Warehouse, Murphy Overseas, and two facilities in Watsonville, California from Dreisbach Enterprises and in September 2014, opened a new temperature-controlled warehouse in Santa Maria, California. In January 2015, Lineage acquired the Pacific Northwest cold storage facilities of Columbia Colstor, headquartered in Moses Lake, Washington.
=== Memes === Internet Memes have become more popular in recent years, with many online platforms sharing content that reflects the experiences of people with various mental health conditions, such as anxiety, borderline personality disorder, suicidal thoughts, and depression. Many individuals use memes to lighten their emotional burdens, find humor in their struggles, and connect with others who are going through similar experiences. A study found that 47% of college students reported using internet memes as a way to ease their psychiatric symptoms. Memes can also portray mental health struggles as trendy or appealing rather than focusing on the actual difficulties these issues cause. Memes featuring "Literally Me" characters dealing with mental illness have become increasingly popular over time, largely because of the widespread appeal of internet memes. The film American Psycho features Patrick Bateman, while Joker focuses on the Joker, with both characters being portrayed as "Literally Me" figures struggling with mental illness. Yet, their illnesses are still admired and glorified in popular culture.
Sources: en.wikipedia.org
==== Partitioning ==== ParM: this protein forms dynamic filaments that push plasmid copies to opposite poles of the cell ParR: recruits ParM to the plasmid by acting as a DNA-binding protein that recognizes the ParC centromere-like site. ParC: the centromere-like site where ParR binds.
In 2010, Medpace acquired the Minneapolis medical-device consultancy Symbios and Germany's Medical Consulting Dr. Schlichtiger GmbH. In 2012 they acquired MediTech BV, a medical device consultancy based in the Netherlands.
Protein function is heavily dependent on protein structure, and rational protein design uses this relationship to design function by designing proteins that have a target structure or fold. Thus, by definition, in rational protein design the target structure or ensemble of structures must be known beforehand. This contrasts with other forms of protein engineering, such as directed evolution, where a variety of methods are used to find proteins that achieve a specific function, and with protein structure prediction where the sequence is known, but the structure is unknown. Most often, the target structure is based on a known structure of another protein. However, novel folds not seen in nature have been made increasingly possible. Peter S. Kim and coworkers designed trimers and tetramers of unnatural coiled coils, which had not been seen before in nature. The protein Top7, developed in David Baker's lab, was designed completely using protein design algorithms, to a completely novel fold. More recently, Baker and coworkers developed a series of principles to design ideal globular-protein structures based on protein folding funnels that bridge between secondary structure prediction and tertiary structures. These principles, which build on both protein structure prediction and protein design, were used to design five different novel protein topologies.
Sources: en.wikipedia.org
No. It is not approved as a therapeutic drug by major regulators. It is sold for research purposes in many settings, which is not the same as clinical approval.
It is classified among peptide hormones and related substances that are prohibited in sport. The ban reflects anti-doping rules rather than a judgment that the peptide is effective for performance enhancement.
Human studies are limited and have not produced consistent evidence of meaningful clinical benefit. Some early trials examined metabolic endpoints, but larger confirmatory trials are generally lacking.
Yes, the World Anti-Doping Agency classifies AOD-9604 as a prohibited peptide hormone and related substance. Its use by athletes is banned under the relevant anti-doping code.